atl1102
Nucleic acidexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 18, 2023 (NCT05938023)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Integrin alpha-4ANTISENSE INHIBITOR
ITGA4 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05938023 | Phase 2 | May 18, 2023 | Antisense Therapeutics Limited, University of London |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Antisense Therapeutics Limited | For profit | 1 | 1 | 1 | 2023 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1